ロード中...
Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China
BACKGROUND: Nab-paclitaxel plus gemcitabine (AG) has resulted in higher tumor response and survival rates for metastatic or advanced pancreatic ductal adenocarcinoma (PDAC) compared with gemcitabine (GEM) alone. AIM: To examine the feasibility and safety of AG adjuvant chemotherapy of resectable PDA...
保存先:
| 出版年: | World J Clin Cases |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Baishideng Publishing Group Inc
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7360710/ https://ncbi.nlm.nih.gov/pubmed/32742988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v8.i13.2778 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|